Sequential multiple assignment randomized trials (SMARTs) have grown in popularity in recent years, and many of their study protocols propose conducting a cost effectiveness analysis of the adaptive strategies embedded within them. The cost effectiveness of these regimes is often proposed to be assessed using incremental cost effectiveness ratios (ICERs). In this paper, we present an estimation and inference procedure for such cost effectiveness measures for the embedded dynamic treatment regimes within a SMART design. In particular, we describe a targeted maximum likelihood estimator for the ICER of a SMART's embedded regimes with influence curve-based inference. We illustrate the performance of these methods using simulations. Throughout, we use as illustration a cost effectiveness analysis for the Adaptive Strategies for Preventing and Treating Lapses of Retention in HIV Care (ADAPT-R; NCT02338739) trial, presenting estimated ICERs (with inference) for embedded regimes aimed at increasing HIV care adherence. This manuscript is one of the first to present cost effectiveness analysis results from a SMART.
翻译:暂无翻译